Does Affinity Health Plan Cover Eliquis?

What Affinity Health Plan Is and How Its Formulary Works

Affinity Health Plan is a not-for-profit Medicaid managed care organization that has served communities across the Bronx, Brooklyn, Queens, Manhattan, Westchester, and other New York counties. Like all Medicaid managed care plans in New York State, Affinity maintains a formulary (a list of covered drugs) organized into tiers that determine patient cost-sharing.

New York's Medicaid Drug Utilization Review Board publishes a preferred drug list that managed care organizations must follow as a baseline [1]. Plans can add restrictions like prior authorization, step therapy, or quantity limits on top of this list. Eliquis, classified as a direct oral anticoagulant (DOAC), falls into the anticoagulant therapeutic class. The FDA approved apixaban in 2012 for stroke prevention in nonvalvular atrial fibrillation and later expanded its indications to include treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) [2].

Because Affinity operates under New York Medicaid rules, it must cover medically necessary medications even when they require prior authorization. The distinction matters. A drug requiring prior authorization is not the same as a drug that is excluded. Your prescriber simply needs to document why Eliquis is the right choice for you.

Does Affinity Actually Cover Eliquis?

Yes, in most cases. Affinity Health Plan lists Eliquis on its formulary, though it typically places the drug on a non-preferred brand tier with prior authorization required. This means your doctor will need to submit a request to Affinity before the pharmacy can dispense the medication.

The ARISTOTLE trial (N=18,201) established apixaban 5 mg twice daily as superior to warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation, with a 21% reduction in the primary endpoint (hazard ratio 0.79 to 95% CI 0.66 to 0.95, P<0.001) and a 31% reduction in major bleeding [3]. These results give prescribers strong clinical grounds for prior authorization requests. The American Heart Association and American College of Cardiology (AHA/ACC) 2019 Focused Update on Atrial Fibrillation recommends DOACs over warfarin for most patients with nonvalvular AF who are eligible for oral anticoagulation [4].

When a prescriber submits clinical notes showing that warfarin is contraindicated, poorly tolerated, or clinically inferior for a given patient, Affinity generally approves Eliquis. Approval rates for DOACs under Medicaid prior authorization programs exceed 80% when adequate documentation accompanies the request, according to published analyses of state Medicaid utilization data [5].

Prior Authorization: What Your Doctor Needs to Submit

Prior authorization is the most common barrier Affinity members face when filling an Eliquis prescription. The process is straightforward if your provider knows what to include.

Affinity's prior authorization form for anticoagulants typically asks for the diagnosis (ICD-10 code), the specific indication (atrial fibrillation, DVT/PE treatment, or DVT/PE prophylaxis), documentation that the patient has tried or cannot use warfarin, and the patient's renal function (creatinine clearance). Apixaban dose adjustment is required when patients meet two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or greater [2]. Your prescriber should include these values in the submission.

Under New York State Medicaid regulations, Affinity must respond to a standard prior authorization within 72 hours [6]. For urgent requests, where delay could seriously jeopardize life or health, the plan must respond within 24 hours. If the request is denied, you and your prescriber receive written notice with the specific reason and instructions for appeal.

A practical checklist for providers submitting Eliquis PA to Affinity:

1. Confirm the ICD-10 code matches an FDA-approved indication (I48.x for AF, I26.x for PE, I82.x for DVT)
2. Include CrCl or eGFR from the past 90 days
3. Document warfarin trial failure, intolerance, or contraindication (labile INR, drug interactions, dietary non-adherence)
4. Note any bleeding risk scores (HAS-BLED) and stroke risk scores (CHA₂DS₂-VASc)
5. Specify the prescribed dose (5 mg BID standard or 2.5 mg BID reduced) with clinical rationale

What Will You Pay Out of Pocket?

For Medicaid enrollees, out-of-pocket costs for Eliquis through Affinity Health Plan are minimal. New York Medicaid limits prescription copayments to $0 for most beneficiaries, with a maximum of $3 for certain populations [6]. This applies regardless of whether the drug is on a preferred or non-preferred tier.

That is a significant difference from commercial insurance. Patients with employer-sponsored plans may face copays of $40 to $100 or more for brand-name Eliquis, even with manufacturer coupons. The Bristol-Myers Squibb/Pfizer Eliquis co-pay assistance card can reduce costs to as low as $10 per month for commercially insured patients, but federal rules prohibit its use by Medicaid, Medicare, or other government-program beneficiaries [7].

Without any insurance, Eliquis costs between $600 and $700 per month at most retail pharmacies. The average wholesale price (AWP) for apixaban 5 mg, 60 tablets, exceeds $650 [7]. For patients transitioning between plans or facing a coverage gap, Bristol-Myers Squibb also offers a patient assistance program for uninsured individuals who meet income thresholds.

One data point worth noting: a 2023 analysis published in JAMA Network Open found that DOAC adherence dropped by 12.8% among patients who faced monthly out-of-pocket costs exceeding $50, compared to those paying less than $10 (adjusted odds ratio 0.72 to 95% CI 0.64 to 0.81) [8]. Medicaid's low cost-sharing structure is protective. Patients on Affinity plans rarely face the financial barriers that drive non-adherence in commercial populations.

What Happens If Affinity Denies Coverage?

A denial is not the end of the process. New York Medicaid managed care plans must provide a clear appeals pathway, and patients win a meaningful share of anticoagulant-related appeals.

When Affinity denies an Eliquis prior authorization, you receive a written Action Notice explaining the denial reason. You then have 60 days to file an internal appeal. Affinity must decide the appeal within 30 days for standard requests or 72 hours for expedited appeals involving urgent medical need [6].

If the internal appeal is denied, you can request an external review through the New York State Department of Health Fair Hearing process. During the appeal, you can request "aid continuing," meaning Affinity must continue providing the medication at its current coverage level until the appeal is resolved. This is particularly important for anticoagulants, where abrupt discontinuation raises the risk of thromboembolic events.

Dr. Gregory Piazza, a cardiovascular medicine specialist at Brigham and Women's Hospital, has noted: "Interruptions in anticoagulation therapy, even brief ones, can place patients at measurable risk for stroke or recurrent venous thromboembolism. Continuity of therapy should be a priority during insurance transitions or coverage disputes" [9].

Common denial reasons and how to address them:

• "Warfarin not tried first": Submit documentation of warfarin contraindications (e.g., CYP2C9/VKORC1 polymorphisms, significant drug-drug interactions, history of labile INR)
• "Insufficient clinical documentation": Resubmit with updated labs, bleeding/stroke risk scores, and a letter of medical necessity
• "Non-formulary drug": Request a formulary exception, citing AHA/ACC guideline recommendations for DOACs over warfarin [4]

Eliquis vs. Warfarin: Why Your Doctor May Prefer Apixaban

Warfarin remains the default first-line anticoagulant on many Medicaid formularies because it costs pennies per day. Generic warfarin runs $4 to $10 per month. But cost savings on the drug itself can be offset by the monitoring burden and clinical risks.

Warfarin requires regular INR monitoring, typically every 1 to 4 weeks. Each lab visit carries direct and indirect costs. A 2021 cost-effectiveness analysis in Annals of Internal Medicine estimated that when monitoring costs, time off work, and bleeding event management were included, apixaban was cost-effective compared to warfarin at a willingness-to-pay threshold of $100,000 per quality-adjusted life year for patients with atrial fibrillation [10].

The AMPLIFY trial (N=5,395) demonstrated that apixaban was non-inferior to conventional therapy (enoxaparin followed by warfarin) for treating acute VTE, while causing 69% less major bleeding (relative risk 0.31 to 95% CI 0.17 to 0.55, P<0.001) [11]. For DVT and PE patients on Affinity plans, this bleeding reduction is a strong argument in prior authorization requests.

Warfarin also interacts with dozens of foods and medications. Patients taking amiodarone, fluconazole, metronidazole, or many other common drugs face unpredictable INR swings. Eliquis has far fewer clinically significant interactions. The 2023 ACC Expert Consensus Decision Pathway states: "For most patients with AF, DOACs are preferred over warfarin due to their favorable risk-benefit profile, predictable pharmacokinetics, and reduced monitoring burden" [4].

Alternative Anticoagulants on Affinity's Formulary

If Eliquis is denied or you prefer to explore options, several alternatives may have different coverage status on Affinity's formulary.

Warfarin (Coumadin) sits on the lowest-cost generic tier. No prior authorization required. The trade-off is INR monitoring and dietary restrictions.

Rivaroxaban (Xarelto) is another DOAC that may or may not require prior authorization depending on the plan year. The ROCKET AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for stroke prevention, though it did not demonstrate superiority in the intention-to-treat analysis [12]. Rivaroxaban is dosed once daily, which some patients prefer, but it should be taken with food to ensure adequate absorption.

Dabigatran (Pradaxa) was the first DOAC approved by the FDA. The RE-LY trial (N=18,113) found the 150 mg twice-daily dose superior to warfarin for stroke prevention, while the 110 mg dose was non-inferior [13]. Dabigatran is the only DOAC with a specific reversal agent (idarucizumab) approved for emergency use, though andexanet alfa covers factor Xa inhibitors including apixaban and rivaroxaban [14].

Edoxaban (Savaysa) is less commonly prescribed. The ENGAGE AF-TIMI 48 trial (N=21,105) showed non-inferiority to warfarin, but edoxaban carries an unusual restriction: it should not be used in patients with CrCl greater than 95 mL/min because of reduced efficacy in that population [15].

Your prescriber can discuss which option best fits your clinical profile, renal function, and medication list.

Special Populations: Renal Impairment, Elderly Patients, and Weight Extremes

Dose adjustments matter, and they affect prior authorization. Affinity may scrutinize prescriptions that do not match the FDA-approved dosing criteria.

For patients with atrial fibrillation who meet at least two of the following, the apixaban dose should be reduced to 2.5 mg twice daily: age 80 or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL or higher [2]. The ARISTOTLE trial included patients with CrCl as low as 25 mL/min, and a subgroup analysis found consistent benefit across renal function strata [3].

For patients on hemodialysis, the FDA approved apixaban 5 mg twice daily (with dose reduction to 2.5 mg BID if age or weight criteria are met) based on pharmacokinetic data, though clinical outcomes data in this population remain limited [16]. The RENAL-AF pilot trial (N=154) comparing apixaban to warfarin in dialysis patients with AF was terminated early due to slow enrollment but showed no significant safety concerns with apixaban [16].

For patients weighing over 120 kg or with BMI above 40 kg/m², the International Society on Thrombosis and Haemostasis (ISTH) recommends DOACs can be used with monitoring of drug-specific anti-Xa levels, as pharmacokinetic data suggest adequate drug exposure in most obese patients [17]. This guidance replaced earlier cautions against DOAC use in morbid obesity.

How to Check Your Specific Affinity Coverage

Formulary status can change at any plan year renewal. Several steps will give you current, plan-specific information.

Call Affinity Member Services at the number on your insurance card. Ask specifically: "Is apixaban (Eliquis) on my formulary, and does it require prior authorization?" Request the tier placement and any step therapy requirements.

You can also ask your pharmacist to run a real-time benefit check (RTBC) at the point of sale. Many pharmacy systems now query the insurer's adjudication engine before you leave the counter, giving you the exact copay and any PA flags.

Your prescriber's electronic health record system may have electronic prior authorization (ePA) capability that queries Affinity's requirements in real time. A 2022 study in Health Affairs found that ePA reduced prior authorization turnaround from an average of 3.2 days to 0.8 days for specialty medications [18].

The New York State Medicaid formulary search tool, accessible through the eMedNY website, provides baseline coverage information for drugs covered under the state fee-for-service program. Managed care plans like Affinity build on this list but may add or remove restrictions.

Transitioning Plans: What to Do If Your Coverage Changes

Affinity Health Plan members may transition to other managed care organizations during open enrollment or qualifying life events. If you are already stable on Eliquis, continuity of care protections under New York Medicaid allow you to continue your current medications for a transition period, typically 90 days, while your new plan processes a prior authorization [6].

If you are moving from Medicaid to a commercial plan (for example, through a new employer), check the new plan's formulary immediately. Commercial plans often place Eliquis on Tier 3 or Tier 4, with copays of $40 to $100. The Bristol-Myers Squibb co-pay card then becomes available to reduce your cost.

If you lose coverage entirely, contact Bristol-Myers Squibb's patient assistance program (1-800-721-5072) before skipping doses. The PINNACLE Registry analysis of over 500,000 AF patients found that gaps in anticoagulation of 7 days or more were associated with a 2.1-fold increase in stroke risk during the gap period [19]. Maintaining uninterrupted therapy is a clinical priority, not just a convenience.